摘要
β受体阻滞剂是心力衰竭患者“金三角”治疗的重要组成部分。目前在心力衰竭合并心房颤动的患者中，β受体阻滞剂多用于改善症状及心功能，但是心房颤动的存在可能降低心力衰竭患者从β受体阻滞剂中的获益。β受体阻滞剂能否改善心力衰竭合并心房颤动患者的预后尚存争议，本文就β受体阻滞剂能否改善心力衰竭合并房颤患者预后的相关研究进展作一综述。
Abstract
β-blockers are an important part of the "Golden Triangle" therapy for patients with heart failure (HF) and have been proven to be effective drugs in the treatment of chronic heart failure. The presence of atrial fibrillation (AF) may reduce or eliminate the prognostic benefit of beta-blockers, which are currently used more for symptom improvement and cardiac function. It is still controversial whether β-blockers can improve the prognosis of patients with both HF and AF. This article reviews the effect of β-blockers on the prognosis of patients with both HF and AF.
万方数据